U54 CA 090810/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2003	2
2004	1
2005	4
2006	3
2007	3
2008	1
2024	0

1

Src continues aging: current and future clinical directions.

Kopetz S, Shah AN, Gallick GE. Kopetz S, et al. Clin Cancer Res. 2007 Dec 15;13(24):7232-6. doi: 10.1158/1078-0432.CCR-07-1902. Clin Cancer Res. 2007. PMID: 18094400 Review.

2

Src, chemoresistance and epithelial to mesenchymal transition: are they related?

Shah AN, Gallick GE. Shah AN, et al. Anticancer Drugs. 2007 Apr;18(4):371-5. doi: 10.1097/CAD.0b013e32801265d7. Anticancer Drugs. 2007. PMID: 17351389 Review.

3

Gemcitabine resistance in pancreatic cancer: picking the key players.

Kim MP, Gallick GE. Kim MP, et al. Clin Cancer Res. 2008 Mar 1;14(5):1284-5. doi: 10.1158/1078-0432.CCR-07-2247. Clin Cancer Res. 2008. PMID: 18316544 No abstract available.

4

Development and characterization of gemcitabine-resistant pancreatic tumor cells.

Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Shah AN, et al. Ann Surg Oncol. 2007 Dec;14(12):3629-37. doi: 10.1245/s10434-007-9583-5. Epub 2007 Oct 2. Ann Surg Oncol. 2007. PMID: 17909916

5

Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.

Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K Jr, Pal A, Bornmann WG, Chiao PJ, Huang P, Xiong H, Abbruzzese JL, McConkey DJ. Nawrocki ST, et al. Cancer Res. 2006 Apr 1;66(7):3773-81. doi: 10.1158/0008-5472.CAN-05-2961. Cancer Res. 2006. PMID: 16585204

6

AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes.

Summy JM, Trevino JG, Lesslie DP, Baker CH, Shakespeare WC, Wang Y, Sundaramoorthi R, Metcalf CA 3rd, Keats JA, Sawyer TK, Gallick GE. Summy JM, et al. Mol Cancer Ther. 2005 Dec;4(12):1900-11. doi: 10.1158/1535-7163.MCT-05-0171. Mol Cancer Ther. 2005. PMID: 16373705

7

The guanine nucleotide exchange factor Tiam1 increases colon carcinoma growth at metastatic sites in an orthotopic nude mouse model.

Minard ME, Herynk MH, Collard JG, Gallick GE. Minard ME, et al. Oncogene. 2005 Apr 7;24(15):2568-73. doi: 10.1038/sj.onc.1208503. Oncogene. 2005. PMID: 15735692

8

Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.

Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ. Davis DW, et al. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):678-89. Clin Cancer Res. 2005. PMID: 15701856

9

The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.

Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. Nawrocki ST, et al. Mol Cancer Ther. 2004 Jan;3(1):59-70. Mol Cancer Ther. 2004. PMID: 14749476

10

Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells.

Nawrocki ST, Carew JS, Dunner K Jr, Boise LH, Chiao PJ, Huang P, Abbruzzese JL, McConkey DJ. Nawrocki ST, et al. Cancer Res. 2005 Dec 15;65(24):11510-9. doi: 10.1158/0008-5472.CAN-05-2394. Cancer Res. 2005. PMID: 16357160

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

14 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year